News

Media

Conferences

Publications

Clinical

Events

Resources

Video

January 11, 2016

The Aftermath of Hepatitis C Drugs on Specialty Spending

Author(s):

Davy James, Managing Editor

David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.

David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos

Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com

Image credit: Sebastian Kaulitzki | stock.adobe.com

Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue

Health and nutrition: the role of glp-1 in diabetes management with apple and syringe - Image credit: Thanayut | stock.adobe.com

Image credit: Dr_Microbe | stock.adobe.com

Image credit: K KStock | stock.adobe.com

Consent Preferences

Clinical Forums

Editorial Staff

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.